Risks of adverse reactions, product recalls and drug injury litigation
First written in FY2016. 7 of 8 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2026: 6 of 20 companies on the "Worse" side.
36 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「If unexpected adverse reactions occur, product recalls, discontinuation of manufacturing and sales, litigation-related responses, damages claims and sales declines due to reputational damage, among other factors, may have a material impact on operating results and financial condition.」
The risks of recalls, discontinuation of sales, litigation, damages claims and reputational damage associated with adverse reactions, as well as mitigation measures such as insurance coverage, are reaffirmed. - FY2025RestatedAnnual report
「Unexpected adverse reactions may result in product recalls, discontinuation of manufacturing and sales, litigation-related responses, damages claims and sales declines due to reputational damage, among other events, and may have a material impact on operating results and financial condition.」
The risks of recalls, discontinuation of sales, litigation, damages claims and reputational damage associated with adverse reactions, as well as mitigation measures such as insurance coverage, are reaffirmed. - FY2022RestatedAnnual report
「Unexpected adverse reactions may result in product recalls, discontinuation of manufacturing and sales, litigation-related responses, damages claims and sales declines due to reputational damage, among other events, and may have a material impact on operating results and financial condition.」
The risks of recalls, discontinuation of sales, litigation, damages claims and reputational damage associated with adverse reactions are reaffirmed. - FY2021RestatedAnnual report
「Unexpected adverse reactions may result in product recalls, discontinuation of manufacturing and sales, litigation-related responses, damages claims and sales declines due to reputational damage, among other events, and may have a material impact on operating results and financial condition.」
The risks of product recalls, discontinuation of sales, litigation, damages claims and reputational damage associated with adverse reactions are reaffirmed. - FY2020RestatedAnnual report
「Unexpected adverse reactions may result in product recalls, discontinuation of manufacturing and sales, litigation-related responses, damages claims and sales declines due to reputational damage, among other events, and may have a material impact on operating results and financial condition.」
The risks of product recalls, discontinuation of sales, litigation and damages claims associated with adverse reactions are reiterated. - FY2019RestatedAnnual report
「Unexpected adverse reactions may result in product recalls, discontinuation of manufacturing and sales, or product liability litigation, among other events, and may have a material impact on operating results and financial condition.」
The risks of product recalls, discontinuation of sales and product liability litigation associated with adverse reactions are reiterated. - FY2018RestatedAnnual report
「Unexpected adverse reactions may result in product recalls, discontinuation of manufacturing and sales, or product liability litigation, among other events, and may have a material impact on operating results and financial condition.」
The risk of recalls, discontinuation of sales and litigation associated with adverse reactions is reiterated. - FY2016First statedAnnual report
「Unexpected adverse reactions may result in product recalls, discontinuation of manufacturing and sales, or product liability litigation, among other events, and may have a material impact on operating results and financial condition.」
This was described as a potential risk, despite efforts to ensure the quality of pharmaceuticals.